Baixinan-B (02185) rose nearly 7%. As of press release, it was up 6.99% to HK$4.44, with a turnover of HK$1,218,000.
The Zhitong Finance app learned that Baixinan-B (02185) rose nearly 7%. As of press release, it had risen 6.99% to HK$4.44, with a turnover of HK$1,218,000.
According to the news, Medtronic recently announced that its radiofrequency ablation system, called Symplicity Spyral, has been approved for listing by the US FDA, making it the second approved RDN product after Recor Medical's Paradise ultrasound system. The treatment will be used to treat patients with uncontrolled high blood pressure with medication. Up to now, 2 renal artery sympathomimetic ablation products have been approved for marketing worldwide, and more than 10 similar treatments are being studied in China.
Minsheng Securities pointed out that the number of patients with refractory hypertension is huge, and the development and use of drug plans is gradually entering a bottleneck period. The RDN surgical treatment plan is expected to solve market pain points and open up incremental markets. Relevant equipment supplies may become a heavyweight segmentation circuit in the field of innovative devices. It is recommended to focus on actively developing RDN treatment devices such as Baixin'an. Debon Securities said that Baixin'an's RDN product has strong advantages and is ahead in domestic progress, and is expected to be approved in 2024.